Search Medical Condition
Please enter condition
Please choose location from dropdown

Essen-Werden, Germany Clinical Trials

A listing of Essen-Werden, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (345) clinical trials

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel )

This is a randomized phase III open-label, multicenter trial evaluating standard induction therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML; in the investigational arm, consolidation therapy is followed by a one-year maintenance therapy with dasatinib. ...

Phase

0.0 miles

Learn More »

A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

Phase

0.83 miles

Learn More »

Registry Study on Patient Characteristics Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

This is a registry study in adult patients with newly diagnosed or refractory/relapsed myeloid neoplasms Investigator's sites: 60-70 sites in Germany and Austria Estimated duration of observation of an individual patient: 10 years maximum Objectives To register all patients with acute myeloid leukemia and related precursor neoplasms, acute leukemia of ...

Phase N/A

0.83 miles

Learn More »

European Trial of Pirfenidone in BOS A European Multi-center Study

Title of the study: A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-2 in lung transplant recipients Study design: Randomized double blinded, placebo controlled study. Eligible patients are to be randomized in a 1:1 ratio to receive either Pirfenidone 2403 mg/d or the matching placebo treatment ...

Phase

0.83 miles

Learn More »

Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease

A multicenter, multinational, prospective study to clarify, whether the addition of cryobiopsy can avoid surgical lung biopsy in a clinically relevant proportion of patients with suspected Idiopathic Interstitial Pneumonia

Phase N/A

0.83 miles

Learn More »

Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING

Interstitial lung diseases (ILD) are a heterogeneous group of more than 200 entities that can be idiopathic or as a result of other diseases and/or treatments. All forms of ILD are considered to be seldom or very seldom (and most of them are so-called "orphan" diseases), in their entirety they ...

Phase N/A

0.83 miles

Learn More »

Entyvio (Vedolizumab) Long Term Safety Study

The drug being tested in this prospective, observational study is called vedolizumab. Vedolizumab is being used to treat people who have UC or CD. This study will look at the long-term safety of vedolizumab versus other biologic agents in participants with UC or CD. The study will enroll approximately 5000 ...

Phase N/A

0.83 miles

Learn More »

Dose-finding Study to Assess the Efficacy Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or placebo is given in addition to the local standard care.

Phase

0.83 miles

Learn More »

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Sirukumab is a fully human anti-interleukin-6 (IL-6) immunoglobulin G1-kappa with a high affinity and specificity for binding to the human IL-6 molecule that may have therapeutic benefit in the treatment of giant cell arteritis (GCA) by interruption of multiple pathogenic pathways. Sirukumab inhibits IL-6-mediated signal transducer and activator of transcription ...

Phase

0.83 miles

Learn More »

Study of Palbociclib in MLL-rearranged Acute Leukemias

Diagnosis: Acute myeloid leukemia; Acute lymphoblastic leukemia Age 18 years, no upper age limit Study drug: Palbociclib Phase Ib/IIa, open-label Phase Ib: Based on previous experience with 125 mg palbociclib once daily for 21 days followed by 7 days of rest in patients with breast cancer, liposarcoma, non-small cell lung ...

Phase

0.83 miles

Learn More »